Neurogene Inc. (NGNE) Stock Score, Valuation & Financial Research

Neurogene Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NGNE

Neurogene Inc. does not currently have a complete Wall Street Score. The stored market price is USD 27.37. These figures are a research snapshot, not a buy or sell recommendation.

What Neurogene Inc. does

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Neurogene is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on research and development of genetic medicines, funded through capital raises and equity financing, as it works toward regulatory approval and commercialization of its gene therapy candidates.

Products and services

  • The company is developing NGN-401, a gene therapy candidate for Rett syndrome that utilizes proprietary EXACT transgene regulation technology to control protein expression levels.

Brands and product families

  • NGN-401 — Lead gene therapy candidate for the treatment of Rett syndrome. Source

Customer types

Patients with rare neurological diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • University of Edinburgh — A master collaboration and license agreement for research and development projects and exclusive rights to patents and know-how related to EXACT technology and MECP2 cassettes. Source

Competitors and product-market comparisons

  • Gene therapy developers — The company faces competition from other biotechnology and pharmaceutical companies developing gene therapies for Rett syndrome and other rare neurological disorders. Source

Business strengths to evaluate

  • Proprietary EXACT transgene regulation technology Source
  • Breakthrough Therapy designation for NGN-401 Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NGNE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 27.37
Market capitalization:
432.51M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -111.11M
Free cash flow:
USD -78.36M
Cash:
USD 112.49M
Total debt:
USD 8.35M
EPS:
USD -5.51

What stands out

  • Free cash flow is USD -78.36M, negative for the stored period.
  • The balance sheet shows USD 112.49M of cash versus USD 8.35M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 104.14M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NGNE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NGNE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NGNE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NGNE to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of NGNE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NGNE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.